TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.

In many other serious heart or lung diseases it has been shown that physical rehabilitation improves patient's fitness and quality of life. In PAH there are no clear guidelines and in general physical activity has traditionally been discouraged, although evidence for this advice is lacking. Interesting research project in Germany showed significant benefit for in-patient rehabilitation in PAH patients.

In this study we will perform a controlled clinical study of out-patient rehabilitation of patients with PAH. We hypothesize that physical training of patients will result in increased exercise capacity and improved quality of life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): 1, 2
B: Arm Label: Training Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Upper extremity aerobic exercise training | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Other: Alternative upper extremity exercises | Intervention Type: OTHER; Name: Upper extremity aerobic exercise training; Assigned to Arm(s): Training Group | Intervention Type: OTHER; Name: Alternative upper extremity exercises; Assigned to Arm(s): Control Group
C: Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Exercise Group Galileo PAH; Type: ACTIVE_COMPARATOR; Interventions: Device: Exercise Group Galileo PAH | Intervention Type: DEVICE; Name: Exercise Group Galileo PAH; Assigned to Arm(s): Exercise Group Galileo PAH
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: No training | Intervention Type: BEHAVIORAL; Name: Physical training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: No training; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.

In many other serious heart or lung diseases it has been shown that physical rehabilitation improves patient's fitness and quality of life. In PAH there are no clear guidelines and in general physical activity has traditionally been discouraged, although evidence for this advice is lacking. Interesting research project in Germany showed significant benefit for in-patient rehabilitation in PAH patients.

In this study we will perform a controlled clinical study of out-patient rehabilitation of patients with PAH. We hypothesize that physical training of patients will result in increased exercise capacity and improved quality of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: No training | Intervention Type: BEHAVIORAL; Name: Physical training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: No training; Assigned to Arm(s): 2
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Intervention Type: BEHAVIORAL; Name: Walking 45 mins 2x p.w.; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.

In many other serious heart or lung diseases it has been shown that physical rehabilitation improves patient's fitness and quality of life. In PAH there are no clear guidelines and in general physical activity has traditionally been discouraged, although evidence for this advice is lacking. Interesting research project in Germany showed significant benefit for in-patient rehabilitation in PAH patients.

In this study we will perform a controlled clinical study of out-patient rehabilitation of patients with PAH. We hypothesize that physical training of patients will result in increased exercise capacity and improved quality of life.


Options:
A: Arm Label: exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: Control group without exercise training; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): exercise training group
B: N/A
C: Arm Label: Exercise and Respiratory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and Respiratory Training | Intervention Type: BEHAVIORAL; Name: Exercise and Respiratory Training; Assigned to Arm(s): Exercise and Respiratory Training
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: No training | Intervention Type: BEHAVIORAL; Name: Physical training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: No training; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A recent meta-analysis that included over 29.000 individuals found that the odds ratio (OR) of individuals with high brain reserve compared to low was 0.54 (p \< 0.0001), a risk decrease of 46%. Among the factors that influence cognitive reserve, mentally stimulating activities was the most robust factor after controlling for education, age, occupation and other potential confounds. The brain reserve effect was sustained over a median longitudinal follow-up of 7 years. It would be interesting to detect whether a complex cognitive training could show similar effects on the cognitive abilities of patients with mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) as it has been reported in previous studies based on mentally stimulating activities analysis.

The hypothesis is that a complex cognitive training alters the neural networks in both subject groups and this alteration is associated with improvement or stabilization of cognitive and non-cognitive function.

The investigator will perform a complex cognitive training program. Twenty patients with mild AD and twenty four patients with MCI will be recruited in this study. The patients will be randomised in control- and treatment groups.Additionally indirect effects on non-cognitive functions will be evaluated in caregivers of the patients.

The investigators expect that the cognitive and non-cognitive abilities will be changed during the cognitive training. The investigators also expect differences between treatment and control groups.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Device: BrainPalTM | Arm Label: Wait-List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: BrainPalTM; Assigned to Arm(s): Intervention
B: Arm Label: Exercise Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Exercise Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Control | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Group | Intervention Type: BEHAVIORAL; Name: Exercise Control; Assigned to Arm(s): Exercise Control group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: complex cognitive training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: complex cognitive training | Intervention Type: BEHAVIORAL; Name: complex cognitive training; Assigned to Arm(s): 1, 2
D: Arm Label: Computerized Working Memory Training.; Type: SHAM_COMPARATOR; Interventions: Device: Computerized Working Memory Training. | Intervention Type: DEVICE; Name: Computerized Working Memory Training.; Assigned to Arm(s): Computerized Working Memory Training.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.
Brief Summary: The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.


Options:
A: Arm Label: mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): mesalamine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic
C: Arm Label: SPD476 (1.2 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet | Arm Label: SPD476 (2.4 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 2.4g extended release tablet | Arm Label: SPD476 (4.8 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 4.8g extended release tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 1.2g extended release tablet; Assigned to Arm(s): SPD476 (1.2 g) | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 2.4g extended release tablet; Assigned to Arm(s): SPD476 (2.4 g) | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 4.8g extended release tablet; Assigned to Arm(s): SPD476 (4.8 g) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine 800 mg | Arm Label: Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactobacillus casei | Arm Label: Mesalazine plus Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine plus Lactobacillus casei | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalazine placebo plus Lactobacillus casei placebo | Intervention Type: DRUG; Name: Mesalazine plus Lactobacillus casei; Assigned to Arm(s): Mesalazine plus Lactobacillus casei | Intervention Type: DRUG; Name: Mesalazine placebo plus Lactobacillus casei placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mesalazine 800 mg; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Lactobacillus casei; Assigned to Arm(s): Lactobacillus casei

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Prevention of Fall-related Fractures and Other Injuries by Physical Exercise Among Community Dwelling Elderly Women
Brief Summary: 1. Primary objective: to evaluate the effectiveness of a fall prevention exercise program in preventing falls resulting in fractures and other physical traumas.
2. Secondary objectives:

   * to better understand the mechanisms by which physical exercise prevents falls and ensuing injuries (improvement in physical functional abilities, global physical activity level, general physical and psychological wellbeing and self-confidence).
   * to determine the individual factors associated with long-term adherence to the exercise program.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: physical therapy | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: physical therapy; Assigned to Arm(s): Intervention Group
B: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Low-magnitude high-frequency vibration treatment | Intervention Type: DEVICE; Name: Low-magnitude high-frequency vibration treatment; Assigned to Arm(s): Treatment
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Fall prevention exercise program | Intervention Type: OTHER; Name: Fall prevention exercise program; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.
Brief Summary: This 2 arm study will assess the impact of bone marker feedback, using blood sampling and communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. The study will also assess safety, quality of life and patient satisfaction. All patients will receive Bonviva 150mg po monthly, and will be randomized into the bio-feedback or no bio-feedback study arms. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Options:
A: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ibandronate [Bonviva/Boniva] | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 2
D: Arm Label: Concealment (control); Type: OTHER; Interventions: Device: MedSignals pillbox | Arm Label: Disclosure (intervention); Type: EXPERIMENTAL; Interventions: Behavioral: Disclosure of adherence report to clinician, Device: MedSignals pillbox | Intervention Type: BEHAVIORAL; Name: Disclosure of adherence report to clinician; Assigned to Arm(s): Disclosure (intervention) | Intervention Type: DEVICE; Name: MedSignals pillbox; Assigned to Arm(s): Concealment (control), Disclosure (intervention)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm, Open Label, Interventional Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Hemoglobin Levels in Hemodialysis Patients With Chronic Renal Anemia
Brief Summary: This single-arm study will assess the long-term maintenance of hemoglobin levels, safety, and tolerability of once-monthly intravenous administration of Mircera in hemodialysis participants with chronic renal anemia. Those currently receiving darbepoetin alfa, epoetin alfa, or epoetin beta maintenance treatment will receive intravenous Mircera at a starting dose of 120, 200, or 360 micrograms (mcg) per month (based on the erythropoiesis stimulating agent \[ESA\] dose administered on Week -1). Subsequent doses will be adjusted to maintain hemoglobin levels within the country-specific target range (11 to 13 grams per deciliter \[g/dL\] for Switzerland and 10 to 12 g/dL for Austria).


Options:
A: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
B: Arm Label: C.E.R.A. 120, 200, or 360 mcg; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A. 120, 200, or 360 mcg
C: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
D: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.
Brief Summary: The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.


Options:
A: Arm Label: SPD476 (1.2 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (1.2g) | Arm Label: SPD476 (2.4 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (2.4 g) | Arm Label: SPD476 (4.8 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (4.8 g) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD476 (1.2g); Assigned to Arm(s): SPD476 (1.2 g) | Intervention Type: DRUG; Name: SPD476 (2.4 g); Assigned to Arm(s): SPD476 (2.4 g) | Intervention Type: DRUG; Name: SPD476 (4.8 g); Assigned to Arm(s): SPD476 (4.8 g) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic
C: Arm Label: mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): mesalamine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: SPD476 (1.2 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet | Arm Label: SPD476 (2.4 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 2.4g extended release tablet | Arm Label: SPD476 (4.8 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476, MMX™ mesalazine, 4.8g extended release tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 1.2g extended release tablet; Assigned to Arm(s): SPD476 (1.2 g) | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 2.4g extended release tablet; Assigned to Arm(s): SPD476 (2.4 g) | Intervention Type: DRUG; Name: SPD476, MMX™ mesalazine, 4.8g extended release tablet; Assigned to Arm(s): SPD476 (4.8 g) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis
Brief Summary: Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A

Answer: C